Chapter 13 — Further Reading

Tier 1 — Verified canonical

Labels and approvals. DailyMed carries current labeling for setmelanotide (Imcivree), pramlintide (Symlin), and metreleptin (Myalept). Reading setmelanotide's Indications section is the fastest way to see how narrowly a precision-medicine indication is written — it names specific genetic conditions, and the contrast with a GLP-1 agonist's label is instructive.

Drugs@FDA holds the approval records and review documents for all three.

ClinicalTrials.gov — search "setmelanotide," "cagrilintide," and "metreleptin." The setmelanotide entries show enrollment numbers that will surprise anyone used to metabolic trials, and the eligibility criteria are where the molecular-diagnosis requirement becomes concrete.

Endocrine physiology. Williams Textbook of Endocrinology covers the leptin–melanocortin pathway, the monogenic obesities, and amylin. Guyton and Hall covers the appetite circuitry at a more introductory level.

IUPHAR/BPS Guide to Pharmacology (guidetopharmacology.org) has curated entries for the melanocortin receptors, the leptin receptor, the amylin receptor complex, and the ghrelin receptor — the authoritative free source for what is actually established about each.

Tier 2 — Attributed, specifics unverified

On the ob/ob and db/db mice and parabiosis. The classic parabiosis experiments of the 1960s–70s correctly inferred both a circulating satiety factor and a resistance phenomenon before the molecule was identified. This history is well documented in reviews of leptin biology. Specific experimental details vary across accounts.

On leptin's discovery. The ob gene was cloned in 1994 and the protein named leptin. Reports of the commercial value of the rights vary considerably across sources and no figure is quoted here.

On leptin trials in common obesity. Randomized trials of recombinant leptin in common obesity produced modest, inconsistent, dose-dependent weight reduction, far below what the animal model predicted. Circulating leptin is elevated in common obesity in proportion to fat mass.

On congenital leptin deficiency. Leptin replacement in individuals with congenital leptin deficiency produces dramatic normalization of appetite and weight, along with correction of associated endocrine abnormalities. The condition is vanishingly rare. Metreleptin's approved indications concern specified lipodystrophy syndromes; leptin deficiency itself is rarer still.

On amylin. A 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells; native human amylin aggregates, which is why pramlintide was engineered. Pramlintide is approved as an adjunct to mealtime insulin; its clinical use has been limited by administration burden and by hypoglycemia risk in combination with insulin.

On cagrilintide and CagriSema. A long-acting amylin analog and its combination with semaglutide; late-stage program ongoing as of 2026, with reported results in some analyses less dramatic than earlier figures suggested. Check current sources for figures — this book's information is current only to 2026.

On the melanocortin pathway and monogenic obesity. Loss-of-function variants in POMC, the leptin receptor, and MC4R produce severe early-onset obesity; MC4R variants are the most common known monogenic contributor. Prevalence estimates vary substantially by population and ascertainment method.

On setmelanotide. An 8-amino-acid cyclic MC4R agonist approved for chronic weight management in obesity due to specified genetic deficiencies including POMC and leptin receptor deficiency, with the indication subsequently extended to certain related conditions. Trials enrolled small numbers of genetically confirmed patients and reported substantial reductions in both weight and hyperphagia.

On PYY and ghrelin. Both have been extensively pursued as targets without producing an approved weight-management drug. PYY infusion reduces subsequent food intake in humans; nausea has been dose-limiting in several programs. Ghrelin receptor agonists have been pursued for appetite stimulation in cachexia and for growth hormone release, which fits the physiology better than antagonism does.

On dietary effects on GLP-1. Fermentable fiber reaching the distal intestine can increase postprandial GLP-1 secretion, and different macronutrients and food forms produce different responses. The magnitude is modest and the signal is subject to the same ~1–2 minute DPP-4 degradation as any endogenous GLP-1.

Tier 3 — Illustrative and constructed

• The appetite network diagram, the leptin reversal figure, the melanocortin pathway diagram, the "why they fail" summary, the four-reason GLP-1-booster box, and the precision-medicine loop in Case Study 2 are all this book's own teaching devices.
• The worked Field 8 dossier entries for setmelanotide and for GLP-1-booster supplements are demonstrations constructed for this book.
• Figure 13.CS1 renders the real leptin obesity trial literature in this book's six-field format; the format is the book's own, and the figure characterizes a body of work rather than a single paper.
• The paraphrased supplement marketing claims are constructed composites of common real phrasings. No specific product, company, or seller is described.

If you only do one thing

Open the setmelanotide label on DailyMed and read Section 1, Indications and Usage. Then open a GLP-1 agonist label and read the same section.

One names specific genetic conditions and requires molecular confirmation. The other names a BMI threshold and a comorbidity list.

That contrast is the whole chapter. One drug corrects an identified broken step in a countable population; the other modifies a working system in a very large one. Both are legitimate medicine, and almost nothing about the first generalizes to the second.

Looking ahead

Chapter 14 opens Part III with growth hormone, and the evidence environment changes sharply. Part II's compounds mostly had completed randomized trials, approvals, and outcome data. Part III's mostly do not.

Useful preparation: none required. But note the pattern you have just seen four times — leptin in deficiency, setmelanotide in POMC deficiency, mecasermin in IGF-1 deficiency, insulin in type 1 diabetes — all total deficiency, exact replacement, dramatic response. Part III is largely about compounds given to people with no established deficiency at all, and the difference is the chapter's running question.